15 May 2002
Hepatitis B vaccine immunogenicity in patients with chronic HCV infection atone year follow-up: the effect of interferon-alpha therapy.Anna Grzeszczuk, Sławomir Chlabicz, Tadeusz Wojciech Łapiński
Med Sci Monit 2002; 8(5): CR379-383 :: ID: 420833
BACKGROUND: Patients with chronic hepatitis C are at risk of additionalliver damage when infected with other hepatotropic viruses, and should be vaccinated against HAV andHBV. However, the optimal dose and schedule are still being debated. In this study we assessed hepatitisB vaccine immunogenicity in patients with chronic hepatitis C at one-year follow-up. The effect of interferonalpha treatment on vaccine safety and anti-HBs response was also evaluated. MATERIAL/METHODS: 48 hepatitisC patients were enrolled, of whom 12 were on interferon treatment. Recombinant HBV vaccine was administeredon a 0-1-6 month schedule, and anti-HBs titers were measured at months 1, 2, 7, and 18. RESULTS: Theoverall seroprotection rate at month 7 was 72.9% in hepatitis C patients, compared to 90.9% in the controls.Subjects with chronic hepatitis C had significantly lower percentages of good responders: 50% versus90.9%. At month 18, only 34.1% of the HCV patients had seroprotective titers of anti-HBs, compared to90% in the control group. At all study points there were no significant differences in seroconversionrates and seroprotection rates between subgroups of hepatitis C patients receiving interferon or thosewithout antiviral treatment. CONCLUSIONS: Hepatitis C is associated with decreased HBV vaccine response.We suggest that postvaccination anti-HBs testing should be performed in all hepatitis C patients, andadditional vaccine doses should be provided to those without protection. Alternatively, higher dosesof vaccine (40 Kg) may be considered. Treatment with interferon was safe and well tolerated.
Keywords: Adult, Hepacivirus, Hepatitis B Antibodies, Hepatitis B Vaccines, Hepatitis C, Hepatitis C Antibodies, Interferon-alpha, Interferons, Liver, Recombinant Proteins, Time Factors
18 October 2021 : EditorialEditorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic
Med Sci Monit 2021; 27:e935123
11 October 2021 : Clinical ResearchClinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia:...
Med Sci Monit In Press; DOI: 10.12659/MSM.933381
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
18 October 2021 : EditorialEditorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-...
Med Sci Monit 2021; 27:e935123
18 Oct 2021 : Clinical ResearchAdverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasth...
Med Sci Monit In Press; DOI: 10.12659/MSM.933296
13 Oct 2021 : Clinical ResearchEndovascular Repair of Thoracic Aorta Injury: 17 Years of Single-Center Experience
Med Sci Monit In Press; DOI: 10.12659/MSM.934479
11 Oct 2021 : Clinical ResearchChallenges for Polish Community Pharmacists in Provision of Services to Immigrants and Non-Polish-Speakers ...
Med Sci Monit In Press; DOI: 10.12659/MSM.933678
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700